Search

Your search keyword '"Leleu, A"' showing total 489 results

Search Constraints

Start Over You searched for: Author "Leleu, A" Remove constraint Author: "Leleu, A" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
489 results on '"Leleu, A"'

Search Results

1. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

4. Impaired unsaturated fatty acid elongation alters mitochondrial function and accelerates metabolic dysfunction-associated steatohepatitis progression

14. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

15. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

16. Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter study

19. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

21. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

23. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

24. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

31. Residential exposure to ultra high frequency electromagnetic fields emitted by Global System for Mobile (GSM) antennas and amyotrophic lateral sclerosis incidence: A geo-epidemiological population-based study

32. Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders

35. RAS/RAF landscape in monoclonal plasma cell conditions

36. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

37. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

41. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

42. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

43. Prognostic role of circulating exosomal miRNAs in multiple myeloma

44. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

45. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

47. TCL1 expression patterns in Waldenström macroglobulinemia

48. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

49. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Catalog

Books, media, physical & digital resources